☆ 4.3 Article

A multistate modeling and simulation framework to learn dose-response of oncology drugs: Application to bintrafusp alfa in non-small cell lung cancer

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Pharmacology & Pharmacy

Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study

Sreenath M. Krishnan et al.

Summary: This study used data from the IMpower131 study to establish a multistate model framework and investigate the influence of second-line immunotherapies on overall survival analysis. The study found that high PD-L1 expression was associated with a decreased risk of progression, while the presence of liver metastasis indicated a high risk of disease progression. The simulations showed that the addition of atezolizumab to the treatment regimen improved patient survival significantly.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)

添加到收藏夹

Article Oncology

The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents

Carlos Zamora Atenza et al.

Summary: This study analyzed the predictive effect of integrating systemic and tumor PD-L1 in patients with advanced NSCLC receiving PD-(L)1 blockade agents. The results showed that integrating circulating and tumor PD-L1 data can help in deciding the best treatment strategy.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)

添加到收藏夹

Editorial Material Pharmacology & Pharmacy

Pharmacometrics Golems: Exposure-Response Models in Oncology

Akash Khandelwal et al.

Summary: Pharmacometric models are prone to bias, which can undermine the analysis and credibility of causal inference. Advanced methods are being developed and utilized to address these biases, particularly in exposure-response analysis with time-to-event end points.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)

添加到收藏夹

Article Oncology

Model-informed approach for risk management of bleeding toxicities for bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1

Yulia Vugmeyster et al.

Summary: A model-informed dose modification approach was used for risk management of bleeding adverse events associated with Bintrafusp alfa. Dose reduction was implemented based on pharmacokinetic and clinical considerations. Guidance was developed for temporary or permanent treatment discontinuation and restarting of treatment, taking into account the type and grade of bleeding and the risk assessment by investigators.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2022)

添加到收藏夹

Editorial Material Pharmacology & Pharmacy

Toward Project Optimus for Oncology Precision Medicine: Multi-Dimensional Dose Optimization Enabled by Quantitative Clinical Pharmacology

Karthik Venkatakrishnan et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)

添加到收藏夹

Review Oncology

Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients

Jeanne Fourie Zirkelbach et al.

Summary: This article highlights the importance of integrating dose optimization strategies into premarketing drug development and discusses the statistical principles behind it. Poor dose optimization can have negative consequences for patients, making dose optimization essential to maximize efficacy and minimize toxicity.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung Cancer: A systematic review and meta-analysis

Sarah Goring et al.

Summary: This study aimed to estimate the relationship between objective response and survival-based endpoints in first-line advanced non-small cell lung cancer (aNSCLC) by drug class. The results showed that immunotherapy (IO)-based treatments had a significantly larger OS benefit per unit of ORR benefit compared to chemotherapy-only treatments, providing important knowledge regarding the durability and depth of response in IO-based therapies.

LUNG CANCER (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Performance of Cox proportional hazard models on recovering the ground truth of confounded exposure-response relationships for large-molecule oncology drugs

Victor Poon et al.

Summary: This study evaluated the performance of the CoxPH model in uncovering exposure-response relationships when only one dose level of data is available. The results showed that missing important confounders and mis-specifying interactions can lead to inaccurate estimates of the exposure-response slope at both high and low doses. This work provides a simulation workflow that can be applied to clinical datasets and offers a deeper understanding of the impact of confounders on exposure-response relationships inferred by the CoxPH model.

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Multistate model for pharmacometric analyses of overall survival in HER2-negative breast cancer patients treated with docetaxel

Sreenath M. Krishnan et al.

Summary: The study developed a multistate model for analyzing overall survival in tumor patients, and successfully described the transitions between different states while also analyzing overall event and survival data. The model allows for simultaneous estimation of transition rates and their tumor model derived metrics, which can be applied to other cancer types and therapies to provide insights into drug efficacy and aid in early clinical interventions.

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2021)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Metastatic sites as predictors in advanced NSCLC treated with PD-1 inhibitors: a systematic review and meta-analysis

Yangyun Huang et al.

Summary: This study evaluated the prognosis of advanced metastatic NSCLC patients treated with PD-1 inhibitors, finding that metastatic sites such as brain, liver, and bone can impact long-term survival outcomes. Patients with multiple metastatic sites had worse progression-free survival, while patients with brain and liver metastases were more likely to progress.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2021)

添加到收藏夹

Article Mathematical & Computational Biology

A multistate model for early decision-making in oncology

Ulrich Beyer et al.

BIOMETRICAL JOURNAL (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Modelling of the Time-Varying Pharmacokinetics of Therapeutic Monoclonal Antibodies: A Literature Review

Antoine Petitcollin et al.

CLINICAL PHARMACOKINETICS (2020)

添加到收藏夹

Article Pharmacology & Pharmacy

Selection of the Recommended Phase 2 Dose for Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1

Yulia Vugmeyster et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)

添加到收藏夹

Article Oncology

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial

Luis Paz-Ares et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Characterizing Exposure-Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects

Haiqing Isaac Dai et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)

添加到收藏夹

Article Medicine, Research & Experimental

Population Pharmacokinetic Analysis of Bintrafusp Alfa in Different Cancer Types

Justin J. Wilkins et al.

ADVANCES IN THERAPY (2019)

添加到收藏夹

Article Oncology

Are 90% of deaths from cancer caused by metastases?

Hanna Dillekas et al.

CANCER MEDICINE (2019)

添加到收藏夹

Article Oncology

The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors

Andrew A. Davis et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

添加到收藏夹

Article Pharmacology & Pharmacy

Time-Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma

Justin J. Wilkins et al.

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2019)

添加到收藏夹

Article Oncology

Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance

David C. Turner et al.

CLINICAL CANCER RESEARCH (2018)

添加到收藏夹

Article Pharmacology & Pharmacy

Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status

Paul G. Baverel et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)

添加到收藏夹

Article Pharmacology & Pharmacy

Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response

Hongshan Li et al.

JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2017)

添加到收藏夹

Article Pharmacology & Pharmacy

Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis

C. Liu et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)

添加到收藏夹

Article Pharmacology & Pharmacy

Quantitative Characterization of the Exposure-Response Relationship for Cancer Immunotherapy: A Case Study of Nivolumab in Patients With Advanced Melanoma

X. Wang et al.

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)

添加到收藏夹

Article Pharmacology & Pharmacy

Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling

Anne-Gaelle Dosne et al.

JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2016)

添加到收藏夹

Article Oncology

PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis

Francesco Passiglia et al.

ONCOTARGET (2016)

添加到收藏夹

Review Oncology

Understanding cachexia as a cancer metabolism syndrome

P. E. Porporato

ONCOGENESIS (2016)

添加到收藏夹

Article Oncology

Emerging markers of cachexia predict survival in cancer patients

Patrizia Mondello et al.

BMC CANCER (2014)

添加到收藏夹

Article Ecology

Gompertz-Makeham life expectancies: Expressions and applications

Trifon I. Missov et al.

THEORETICAL POPULATION BIOLOGY (2013)

添加到收藏夹

Article Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. A. Eisenhauer et al.

EUROPEAN JOURNAL OF CANCER (2009)

添加到收藏夹

Article Oncology

Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics

Laurent Claret et al.

JOURNAL OF CLINICAL ONCOLOGY (2009)

添加到收藏夹

Article Health Care Sciences & Services

Multi-state models for the analysis of time-to-event data

Luis Meira-Machado et al.

STATISTICAL METHODS IN MEDICAL RESEARCH (2009)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.